151 related articles for article (PubMed ID: 36905830)
1. Comprehensive neurological evaluation of a cohort of patients with neurofibromatosis type 1 from a single institution.
Angelova-Toshkina D; Decker JA; Traunwieser T; Holzapfel J; Bette S; Huber S; Schimmel M; Vollert K; Bison B; Kröncke T; Bramswig NC; Wieczorek D; Gnekow AK; Frühwald MC; Kuhlen M
Eur J Paediatr Neurol; 2023 Mar; 43():52-61. PubMed ID: 36905830
[TBL] [Abstract][Full Text] [Related]
2. Optic Pathway Glioma and Cerebral Focal Abnormal Signal Intensity in Patients with Neurofibromatosis Type 1: Characteristics, Treatment Choices and Follow-up in 134 Affected Individuals and a Brief Review of the Literature.
Friedrich RE; Nuding MA
Anticancer Res; 2016 Aug; 36(8):4095-121. PubMed ID: 27466519
[TBL] [Abstract][Full Text] [Related]
3. A molecular analysis of individuals with neurofibromatosis type 1 (NF1) and optic pathway gliomas (OPGs), and an assessment of genotype-phenotype correlations.
Sharif S; Upadhyaya M; Ferner R; Majounie E; Shenton A; Baser M; Thakker N; Evans DG
J Med Genet; 2011 Apr; 48(4):256-60. PubMed ID: 21278392
[TBL] [Abstract][Full Text] [Related]
4. Systematic MRI in NF1 children under six years of age for the diagnosis of optic pathway gliomas. Study and outcome of a French cohort.
Blanchard G; Lafforgue MP; Lion-François L; Kemlin I; Rodriguez D; Castelnau P; Carneiro M; Meyer P; Rivier F; Barbarot S; Chaix Y;
Eur J Paediatr Neurol; 2016 Mar; 20(2):275-281. PubMed ID: 26774135
[TBL] [Abstract][Full Text] [Related]
5. Non-Coding RNA and Tumor Development in Neurofibromatosis Type 1:
Tritto V; Ferrari L; Esposito S; Zuccotti P; Bianchessi D; Natacci F; Saletti V; Eoli M; Riva P
Genes (Basel); 2019 Nov; 10(11):. PubMed ID: 31694342
[TBL] [Abstract][Full Text] [Related]
6. [Prognostic factors of neurofibromatosis type 1-associated optic pathway gliomas in children].
Florent C; Beylerian M; Mairot K; Dambricourt L; André N; David T; Girard N; Audic F; Denis D
J Fr Ophtalmol; 2022 Feb; 45(2):173-184. PubMed ID: 34972579
[TBL] [Abstract][Full Text] [Related]
7. Whole-body MRI evaluation in neurofibromatosis type 1 patients younger than 3 years old and the genetic contribution to disease progression.
Kang E; Kim YM; Choi Y; Lee Y; Kim J; Choi IH; Yoo HW; Yoon HM; Lee BH
Orphanet J Rare Dis; 2022 Jan; 17(1):24. PubMed ID: 35093157
[TBL] [Abstract][Full Text] [Related]
8. Genotype-phenotype associations in neurofibromatosis type 1 (NF1): an increased risk of tumor complications in patients with NF1 splice-site mutations?
Alkindy A; Chuzhanova N; Kini U; Cooper DN; Upadhyaya M
Hum Genomics; 2012 Aug; 6(1):12. PubMed ID: 23244495
[TBL] [Abstract][Full Text] [Related]
9. [Neurofibromatosis type 1 and associated clinical abnormalities in 27 children].
Syrbe S; Eberle K; Strenge S; Bernhard MK; Herbertz S; Bierbach U; Hirsch W; Froster UG; Kiess W; Merkenschlager A
Klin Padiatr; 2007; 219(6):326-32. PubMed ID: 18183640
[TBL] [Abstract][Full Text] [Related]
10. Antiseizure effect of MEK inhibitor in a child with neurofibromatosis type 1-Developmental and epileptic encephalopathy and optic pathway glioma.
Barrière S; Faure-Conter C; Leblond P; Philippe M; des Portes V; Lion François L; de Bellescize J; Sabatier I
Epileptic Disord; 2024 Feb; 26(1):133-138. PubMed ID: 37983638
[TBL] [Abstract][Full Text] [Related]
11. A novel stop-gain
Fukunaga N; Hayashi T; Yamada Y; Mizobuchi K; Ohta A; Nakano T
Ophthalmic Genet; 2024 Apr; 45(2):186-192. PubMed ID: 37599594
[TBL] [Abstract][Full Text] [Related]
12. Natural history of optic pathway gliomas in a cohort of unselected patients affected by Neurofibromatosis 1.
Trevisson E; Cassina M; Opocher E; Vicenzi V; Lucchetta M; Parrozzani R; Miglionico G; Mardari R; Viscardi E; Midena E; Clementi M
J Neurooncol; 2017 Sep; 134(2):279-287. PubMed ID: 28577031
[TBL] [Abstract][Full Text] [Related]
13. Optic pathway glioma and the sex association in neurofibromatosis type 1: a single-center study.
Henning AM; Handrup MM; Kjeldsen SM; Larsen DA; Ejerskov C
Orphanet J Rare Dis; 2021 Nov; 16(1):489. PubMed ID: 34809690
[TBL] [Abstract][Full Text] [Related]
14. Clustering of mutations in the 5' tertile of the NF1 gene in Slovakia patients with optic pathway glioma.
Bolcekova A; Nemethova M; Zatkova A; Hlinkova K; Pozgayova S; Hlavata A; Kadasi L; Durovcikova D; Gerinec A; Husakova K; Pavlovicova Z; Holobrada M; Kovacs L; Ilencikova D
Neoplasma; 2013; 60(6):655-65. PubMed ID: 23906300
[TBL] [Abstract][Full Text] [Related]
15. No correlation between NF1 mutation position and risk of optic pathway glioma in 77 unrelated NF1 patients.
Hutter S; Piro RM; Waszak SM; Kehrer-Sawatzki H; Friedrich RE; Lassaletta A; Witt O; Korbel JO; Lichter P; Schuhmann MU; Pfister SM; Tabori U; Mautner VF; Jones DTW
Hum Genet; 2016 May; 135(5):469-475. PubMed ID: 26969325
[TBL] [Abstract][Full Text] [Related]
16. An update on the central nervous system manifestations of neurofibromatosis type 1.
Nix JS; Blakeley J; Rodriguez FJ
Acta Neuropathol; 2020 Apr; 139(4):625-641. PubMed ID: 30963251
[TBL] [Abstract][Full Text] [Related]
17. Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations.
Listernick R; Ferner RE; Liu GT; Gutmann DH
Ann Neurol; 2007 Mar; 61(3):189-98. PubMed ID: 17387725
[TBL] [Abstract][Full Text] [Related]
18. Optic Pathway Gliomas in Neurofibromatosis Type 1.
Campen CJ; Gutmann DH
J Child Neurol; 2018 Jan; 33(1):73-81. PubMed ID: 29246098
[TBL] [Abstract][Full Text] [Related]
19. Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1.
Freret ME; Gutmann DH
J Neurosci Res; 2019 Jan; 97(1):45-56. PubMed ID: 29704429
[TBL] [Abstract][Full Text] [Related]
20. Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients.
Segal L; Darvish-Zargar M; Dilenge ME; Ortenberg J; Polomeno RC
J AAPOS; 2010 Apr; 14(2):155-8. PubMed ID: 20451859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
